{
    "title": "111_hr4390",
    "content": "The Act titled \"Medicare and Medicaid Fraud Prevention and Control Act of 2009\" enhances program and provider protections in the Medicare, Medicaid, and CHIP programs. The Act titled \"Medicare and Medicaid Fraud Prevention and Control Act of 2009\" enhances program and provider protections in the Medicare, Medicaid, and CHIP programs by authorizing screening, enhanced oversight periods, enrollment moratoria, and periodic validations based on significant risk of fraudulent activity. The Act \"Medicare and Medicaid Fraud Prevention and Control Act of 2009\" allows the Secretary to impose requirements on providers or suppliers enrolling in Medicare, Medicaid, or CHIP programs, including screening, enhanced oversight periods, enrollment moratoria, and periodic validations. States may also be required to implement these provisions in their State plans. The Secretary may require States to implement screening procedures for providers and suppliers enrolling in Medicare, Medicaid, or CHIP programs. Screening may include licensing board checks, exclusion list screenings, background checks, and site visits. Actions and determinations made under this subsection are not subject to judicial review. The Secretary may require enhanced oversight procedures for providers and suppliers enrolling in Medicare, Medicaid, or CHIP programs, including site visits, inspections, prepayment review, and claims review. This period of enhanced oversight can last between 30 to 365 days. The Secretary may require enhanced oversight procedures for providers and suppliers enrolling in Medicare, Medicaid, or CHIP programs, including site visits, inspections, prepayment review, and claims review. This period of enhanced oversight can last between 30 to 365 days. Additionally, the Secretary may extend the oversight period for more than 365 days if deemed necessary. Enhanced oversight for claims of durable medical equipment suppliers involves withholding payment for specified periods if fraudulent activity is suspected. The Secretary may establish enhanced oversight procedures for providers and suppliers enrolling in Medicare, Medicaid, or CHIP programs, including site visits, inspections, prepayment review, and claims review. This oversight period can last between 30 to 365 days and may be extended if necessary. Payment under title XVIII for durable medical equipment furnished by suppliers suspected of fraudulent activity can be withheld for specified periods. Additionally, a program for periodic review of physician authorizations will be established to address excessive prescribing or authorization of items or services. The Secretary may impose a moratorium on provider and supplier enrollment in Medicare, Medicaid, or CHIP programs if serious ongoing fraud is detected. Providers must validate claims within 90 days or face denial of future claims. The Secretary may impose a moratorium on provider and supplier enrollment in Medicare, Medicaid, or CHIP programs if serious ongoing fraud is detected. A probationary period is established to determine the legitimacy of new providers and suppliers. States can engage in enhanced provider oversight activities beyond those required by the Secretary. The Secretary may impose a moratorium on provider and supplier enrollment in Medicare, Medicaid, or CHIP programs if serious ongoing fraud is detected. A probationary period of heightened review is established for new providers and suppliers, during which the legitimacy of operations and physician prescriptions are validated. States can conduct enhanced provider oversight activities beyond those mandated by the Secretary. The Secretary can impose a moratorium on provider and supplier enrollment in Medicare, Medicaid, or CHIP programs in case of serious ongoing fraud. A probationary period of heightened review is set for new providers and suppliers to validate the legitimacy of operations and physician prescriptions. If a significant number of claims are found to be illegitimate, the Secretary may suspend or terminate the participation of the provider or supplier. The Secretary can also impose a civil monetary penalty of up to $10,000 for non-cooperation in validating prescriptions or authorizations. The Secretary may impose a civil monetary penalty of up to $10,000 on a physician or professional for failing to cooperate in validating prescriptions. Additionally, certain prompt pay provisions are revised to exclude claims from providers or suppliers showing suspicious patterns of claim submission. The Secretary may impose penalties on providers for failing to validate prescriptions. Certain prompt pay provisions are revised to exclude claims from providers with suspicious claim submission patterns. The Secretary may impose penalties on providers for failing to validate prescriptions and exclude claims from providers with suspicious claim submission patterns. State plans must enforce determinations made by the Secretary regarding fraudulent activity and carry out required activities for program integrity. The Secretary may impose penalties on providers for failing to validate prescriptions and exclude claims with suspicious patterns. State plans must enforce Secretary's determinations on fraudulent activity and carry out required activities for program integrity. The Secretary of Health and Human Services may consult with the Inspector General to identify providers and suppliers at risk of fraudulent activity under Medicare, Medicaid, or the State children's health insurance program. Additional funding is authorized for these efforts. The Secretary of Health and Human Services may consult with the Inspector General to identify providers and suppliers at risk of fraudulent activity under Medicare, Medicaid, or the State children's health insurance program. Additional funding is authorized for these efforts, with amendments taking effect upon the enactment of the Act. The Act will be effective upon enactment, with regulations to be implemented within 6 months. The Secretary of Health and Human Services will issue interim final regulations immediately upon publication, allowing for public comments and potential revisions."
}